Advanced Search

 

Study ID Status Title Patient Level Data
759348/007 Completed A randomized, controlled, phase II study to evaluate the safety and immunogenicity of five formulations of GlaxoSmithKline Biologicals’ investigational vaccination regimen, when administered intramuscularly as a 3-dose primary immunization schedule (2-3-4 month schedule) before 6 months of age.
763674/001 Completed A phase II, open, randomized, controlled study to evaluate an investigational vaccination regimen administered as athree dose primary vaccination course at 2, 3 and 4 months of age. Study Listed on ClinicalStudyDataRequest.com
763674/002 Completed A phase II open, randomized, controlled study to evaluate an investigational vaccination regimen administered as athree dose primary vaccination course at 2, 3 and 4 months of age. Study Listed on ClinicalStudyDataRequest.com
776423/001 Completed A phase III, observer-blinded randomised, multi-centre clinical study of the safety, immunogenicity and consistency of three manufacturing lots of GSK Biologicals' candidate Tdap vaccine as compared to a US-licensed Td vaccine when given as a booster dose to healthy adolescents (10-18 years of age) Study Listed on ClinicalStudyDataRequest.com
792014/001 Completed A phase II, open (partially double-blind), randomised, controlled, multicentre, primary vaccination study to evaluate the immunogenicity (including immune memory), reactogenicity and safety of three different formulations of the GSK Biologicals’ combined Haemophilus influenzae type b-meningococcal serogroups CY conjugate vaccine given concomitantly with Infanrix® penta and Prevenar®, versus ActHIB® and Meningitec® given concomitantly with Infanrix® penta and versus ActHIB® given concomitantly with Infanrix® penta and Prevenar® in infants according to a 2-4-6 month schedule. Study Listed on ClinicalStudyDataRequest.com
792014/002 Completed A phase II, open, randomized, controlled, multicentre, primary vaccination study to evaluate the immunogenicity, reactogenicity and safety of an investigational vaccination regimen versus ActHIB® and Menjugate® given concomitantly with Infanrix® penta and Prevenar® in infants Study Listed on ClinicalStudyDataRequest.com
792014/003 Completed A phase II, open (partially double-blind), randomised, controlled, multicentre, primary vaccination study to evaluate the immunogenicity, reactogenicity and safety of three different formulations of GSK Biologicals’ combined Haemophilus influenzae type b-meningococcal serogroups C and Y- conjugate vaccine and one formulation of GSK Biologicals’ Haemophilus influenzae type b-meningococcal serogroup C conjugate vaccine each given concomitantly with InfanrixTM penta, versus MeningitecTM, given concomitantly with InfanrixTM hexa in infants according to a 2-3-4 month schedule Study Listed on ClinicalStudyDataRequest.com
797620/001 Completed A dose proportionality study with a combination tablet formulation of rosiglitazone and glimepiride (4mg/1mg; or 4mg/2mg; or 4mg/4mg) in healthy subjects. Study Listed on ClinicalStudyDataRequest.com
797620/002 Completed A bioequivalence study with a combination tablet formulation of rosiglitazone and glimepiride (4mg/4mg) compared to concomitant dosing of rosiglitazone 4mg and glimepiride 4mg (4mg + 4mg) commercial tablets in healthy subjects Study Listed on ClinicalStudyDataRequest.com
797620/003 Completed A study to assess effect of food on pharmacokinetics of an investigational formulation, and to compare the pharmacokinetics of an investigational formulation to concomitant dosing of rosiglitazone 4mg and glimepiride 4mg commercial tablets in the fed state in healthy subjects Study Listed on ClinicalStudyDataRequest.com
797620/004 Completed A multi-center, randomized, double-blind, parallel group trial to compare the efficacy and safety of fixed-dose rosiglitazone/glimepiride combination therapy to glimepiride monotherapy and rosiglitazone monotherapy in drug naïve subjects with type 2 diabetes mellitus Study Listed on ClinicalStudyDataRequest.com
811936/001 Completed Phase 2, open, randomized, controlled study to demonstrate the non-inferiority of the meningococcal serogroup C immune response and the superiority of the Hib immune response of GSK Biologicals’ Haemophilus influenzae type b-meningococcal C-TT conjugate vaccine administered with Infanrix™ penta versus Meningitec™ administered with Infanrix™ Study Listed on ClinicalStudyDataRequest.com
811936/003 Completed A phase 3, open, randomized, controlled, multicentre study to evaluate the safety and reactogenicity profile of GSK Biologicals' Haemophilus influenzae type b–meningococcal serogroup C conjugate candidate vaccine given concomitantly with GSK Biologicals' diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine and to compare it with MenC-CRM197 conjugate vaccine co-administered with GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine, when given as a 3-dose primary vaccination (at 2, 3, 4 months of age) to healthy infants. Study Listed on ClinicalStudyDataRequest.com
A4A10003 Completed A randomised, double-blind, placebo-controlled, 3-way cross-over study to investigate the effects of pre-treatment with single inhaled doses of an NCE and fluticasone propionate on the allergen induced late phase asthmatic response in mild asthmatic subjects. Study Listed on ClinicalStudyDataRequest.com
A4A10008 Completed An 8-day, randomised, placebo-controlled, three-way crossover trial of repeat doses of a new chemical entity (NCE), fluticasone propionate and placebo administered intranasally, blinded for fluticasone propionate versus placebo, in an environmental exposition unit, the Vienna Challenge Chamber (VCC) in subjects with seasonal allergic rhinitis (SAR) Study Listed on ClinicalStudyDataRequest.com
AA210005 Completed A randomised, double-blind, placebo-controlled, cross-over study to investigate the effects of pre-treatment with repeat inhaled doses of a new chemical entity on the allergen-induced late phase asthmatic response in mild asthmatic subjects. Study Listed on ClinicalStudyDataRequest.com
AA210012 Completed A randomised, double-blind, double dummy, placebo-controlled, three-way, balanced incomplete block, crossover study in patients with allergic rhinitis to compare the effect versus placebo of 7 days treatment with a new chemical entity (NCE) and 7 days treatment with intranasal fluticasone propionate 200 μg BID upon nasal clinical response after intranasal allergen challenge. Study Listed on ClinicalStudyDataRequest.com
AA210013 Completed A randomised, double-blind, placebo-controlled, crossover study to investigate the effects of pre-treatment with inhaled repeat doses of a new chemical entity (NCE) on the allergen induced late phase asthmatic response in mild asthmatic subjects. Study Listed on ClinicalStudyDataRequest.com
AC2103473 Completed A randomised, double blind, placebo-controlled, double dummy, 4-way cross-over, dose ascending study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single inhaled doses of GSK233705 and tiotropium bromide (18µg) via DPI in COPD patients Study Listed on ClinicalStudyDataRequest.com
AC2105333 Completed A Randomised, Double-Blind, Placebo-Controlled, Dose Ascending, 3 Period Crossover Study To Examine The Safety, Tolerability, Pharmacodynamics And Pharmacokinetics Of Repeat Inhaled Doses Of GSK233705B In COPD Subjects. Study Listed on ClinicalStudyDataRequest.com
AC2106213 Completed A single-centre, open-label, sequential ascending cross over study to examine safety, tolerability, pharmacodynamics and pharmacokinetics of ascending single doses, nominally 10, 30, 70 and 110µg intravenous doses and a single 250µg oral dose of GSK233705 in healthy volunteers. Study Listed on ClinicalStudyDataRequest.com
AC2106956 Completed A multicentre, randomised, partially blinded, placebo-controlled, three-way crossover, incomplete block design study to investigate the safety, tolerability, pharmacodynamics/ efficacy and pharmacokinetics of dual bronchodilator therapy with salmeterol 50µg twice-daily plus two different doses of GSK233705B (20 and 50µg twice-daily), compared with placebo, salmeterol 50µg twice-daily alone, and Tiotropium 18µg once-daily alone, in subjects with chronic obstructive pulmonary disease Study Listed on ClinicalStudyDataRequest.com
AC2108378 Completed A randomised, double-blind, placebo-controlled, dose ascending, 2-cohort, parallel group study to examine the safety, tolerability, pharmacokinetics and pharmacodynamics of twice-daily inhaled doses of GSK233705B formulated with the excipient Magnesium Stearate in COPD subjects for 7-days. Study Listed on ClinicalStudyDataRequest.com
AC2108380 Completed A single-centre, randomized, double-blind placebo-controlled, dose-ascending, cross-over study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK233705, formulated with the excipient magnesium stearate, in healthy volunteers Study Listed on ClinicalStudyDataRequest.com
AC2110664 Completed Dose-Ranging Study for GSK233705B Delivered Once Daily in Subjects with COPD Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.